Protalix BioTherapeutics
PLX | AMEX
$3.03
-$0.02 (-0.66%)
At close: Nov 16, 2026, 4:00 PM ET
$2.98
-$0.05 (-1.65%)
After-hours:
Nov 16, 2026, 7:17 PM ET
Protalix BioTherapeutics Company Profile
Company profile explainedCompany Profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Key Executives
| Name | Position |
|---|---|
| Dror Bashan | President, Chief Executive Officer & Director |
| Gilad Mamlok | Senior VP, CFO Treasurer & Secretary |
| Yael Fellous | Vice President of Human Resources |
| Yaron Naos | SVP & COO |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 09, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
Protalix BioTherapeutics
| Country | United States |
| IPO Date | May 15, 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 226 |
| CEO | Dror Bashan |
Contact Details
2 University Plaza Hackensack,
New Jersey 07601 United States
Stock Details
| Ticker Symbol | PLX |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001006281 |
| CUSIP Number | 74365A309 |
| ISIN Number | US74365A3095 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove PLX